Literature DB >> 3874382

Ocular involvement in patients with fungal infections.

P J McDonnell, J M McDonnell, R H Brown, W R Green.   

Abstract

Autopsy findings of 133 patients who died following fungemia or with invasive fungal infection were reviewed. Common clinical factors included antibiotic therapy, chemotherapy, corticosteroid administration, hyperalimentation, malignancy, and bone marrow transplantation. Fungal infection was seldom diagnosed antemortem and fungemia was detected in only 24 patients (18%). Ocular involvement occurred in 14 patients (Candida 11, Aspergillus 2, and Cryptococcus 1). The eye was the fifth most commonly involved organ at autopsy among patients with candida infection. Ocular involvement occurred with a significantly greater frequency in patients with Candida tropicalis than with Candida albicans infections (P less than 0.05). Although only about 10% of patients with fungal infections had ocular involvement, all those with ocular lesions had widely disseminated disease. Realizing the potential toxicity of antifungal therapy, we recommend that screening ophthalmologic examinations be performed on patients with fungemia or patients at high risk for development of fungal infection. The presence of ocular lesions consistent with fungal disease, in the appropriate setting, is a strong indication for investigation of possible systemic fungal infection and therapy once a definitive diagnosis is established.

Entities:  

Mesh:

Year:  1985        PMID: 3874382     DOI: 10.1016/s0161-6420(85)33989-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

1.  Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report.

Authors:  Shakhsanam E Aliyeva; Andrew J Ullmann; Ulrike B Kottler; Martine Frising; Oliver Schwenn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-03-30       Impact factor: 3.117

2.  Candidemia complicated by endophthalmitis: a prospective analysis.

Authors:  S Kannangara; D Shindler; D Y Kunimoto; B Sell; J A DeSimone
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

3.  Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection.

Authors:  Hideaki Kato; Yukihiro Yoshimura; Yoshihiro Suido; Kazuo Ide; Yoshifumi Sugiyama; Kasumi Matsuno; Hideaki Nakajima
Journal:  Infection       Date:  2018-06-29       Impact factor: 3.553

4.  Outcomes, impact on management, and costs of fungal eye disease consults in a tertiary care setting.

Authors:  Devon H Ghodasra; Kian Eftekhari; Ankoor R Shah; Brian L VanderBeek
Journal:  Ophthalmology       Date:  2014-08-10       Impact factor: 12.079

5.  A comparative clinicopathologic study of endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared to aspergillosis.

Authors:  N A Rao; A Hidayat
Journal:  Trans Am Ophthalmol Soc       Date:  2000

6.  Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis.

Authors:  D V Savani; J R Perfect; L M Cobo; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

7.  Diagnostic pars plana vitrectomy report of a 21-year retrospective study.

Authors:  G N Palexas; W R Green; M F Goldberg; Y Ding
Journal:  Trans Am Ophthalmol Soc       Date:  1995

8.  Ocular manifestations of HIV infection.

Authors:  D A Jabs
Journal:  Trans Am Ophthalmol Soc       Date:  1995

9.  Bone-marrow transplantation and toxoplasmic retinochoroiditis.

Authors:  D Pauleikhoff; E Messmer; D W Beelen; M Foerster; A Wessing
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

10.  Endophthalmitis in patients with disseminated fungal disease.

Authors:  Stephen S Feman; John C Nichols; Sophia M Chung; Todd A Theobald
Journal:  Trans Am Ophthalmol Soc       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.